This phase 0 study aimed to evaluate PTP-01's ability to target CSP in pancreatic tumors, despite their dense desmoplastic stroma, and to estimate CSP density and tumor vascularity.<h4>Methods</h4>Pancreatic cancer patients (n = 3) received an intravenous injection of 100 μg PTP-01 labeled with 370 MBq <sup>111</sup>In one day before resection. This evidence concerns the gene DNAJC5 and pancreatic neoplasm.